Toronto wife-husband research team lose bid to re-open labs

Shereen Ezzat. Source: University Health Network
Sylvia Asa. Source: University of Toronto

A pair of Canadian scientists may be running out of options to save their laboratories, which have been permanently closed based on findings of research misconduct.

Sylvia Asa, once the head of the largest hospital diagnostic laboratory in Canada, and her husband and collaborator Shereen Ezzat, have spent almost five years fighting allegations of research misconduct involving data falsification and fabrication in more than a dozen published papers. The couple’s work has been scrutinized by their employer, University Health Network (UHN), a healthcare system affiliated with the University of Toronto, in two investigations. The investigations did not find evidence that Asa or Ezzat were directly involved in image falsification or fabrication; however, they concluded that, as supervisors, they failed to conform to accepted standards and practices as they related to scientific rigor and accountability.

After the first investigation, UHN decided to temporarily close both Asa and Ezzat’s labs. After the second, the UHN decided to make that closure permanent. The couple have had three papers retracted and at least one correction.

Recently, the pair faced yet another setback. After they asked an Ontario court to review two of UHN’s decisions, on July 13, a judge found no fault with either one. Justice Ian Nordheimer, one of three judges who considered Asa and Ezzat’s request, said in his written opinion Continue reading Toronto wife-husband research team lose bid to re-open labs

Journal retracts paper it says authors published twice. Authors disagree.

A journal has retracted a 2012 paper after determining that the authors had already published it elsewhere.

According to the retraction notice, the editors-in-chief of the Journal of Occupational Medicine and Toxicology concluded that the article had  been published in another journal—In Vitro Cellular & Developmental Biology – Animal—the previous month. The authors, however, did not agree to the retraction.

The research, led by Ali Khavanin, who is based at Tarbiat Modares University in Tehran, Iran and is corresponding author on both papers, evaluated whether the vibrations from industrial machinery can harm hearing in rabbits (1, 2).

Here’s the retraction notice for “Assessment of the influence of whole body vibration on Cochlear function”: Continue reading Journal retracts paper it says authors published twice. Authors disagree.

Why did it take a journal two years to retract a paper after a misconduct finding?

A 2014 paper containing data manipulated by a former graduate student has finally been retracted, two years after the U.S. Office of Research Integrity (ORI) published its findings.

In August 2015, the ORI published a report that Peter Littlefield, who was working on his PhD at the University of California, San Francisco (UCSF), had committed “research misconduct by falsifying and/or fabricating data” in two papers. Littlefield agreed to correct or retract the papers–one published in Chemistry & Biology and the other in Science Signaling.  

When we contacted Chemistry & Biology back in August 2015, a spokesperson for Cell Press told us the journal was figuring out “the best way to correct the scientific record.”

Apparently that took two years. In the meantime, the journal did not issue an expression of concern or otherwise notify readers of the issues. Continue reading Why did it take a journal two years to retract a paper after a misconduct finding?

Controversial CRISPR paper earns second editorial note

Against the authors’ objections, Nature Methods has added an expression of concern to a 2017 paper that drew fire for suggesting a common gene editing technique could cause widespread collateral damage to the genome. The latest note — the second to be added in two months — alerts readers to an alternative interpretation of the findings.

When “Unexpected mutations after CRISPR–Cas9 editing in vivo” was published May 30, it immediately drew criticism from many of the top scientists working with CRISPR, including those associated with companies seeking to develop CRISPR-based therapies for humans. Share prices for the two largest companies pursuing CRISPR therapies, Editas Medicine and Intellia Therapeutics, dropped following publication of the article.

On June 14, the journal published a notice to alert readers to “technical criticisms” of the paper. Apparently, that wasn’t sufficient, because the journal is now providing more details on the nature of the criticisms, despite the objections of the paper’s authors:

Continue reading Controversial CRISPR paper earns second editorial note

PLOS ONE retracts paper after researcher admits to fabricating data

On June 19, 2017, the U.S. Office of Research Integrity published its first misconduct finding of the year. The ORI reported that Brandi M. Baughman — a former research training awardee at the National Institute of Environmental and Health Sciences (NIEHS) — had “falsified and/or fabricated data” in 11 figures in a 2016 paper published in PLOS ONE.

Two days later, on June 21, PLOS ONE retracted the paper. (Note: The retraction process proceeded relatively quickly, but took longer than two days; a spokesperson for the journal told us that the authors alerted the editors of their concerns about the publication in May.)   Continue reading PLOS ONE retracts paper after researcher admits to fabricating data

Uni dings schizophrenia studies for problems with informed consent, other flaws

Psychiatry journals have retracted two papers evaluating a schizophrenia drug after a university in Japan flagged issues, such as a lack of written informed consent.

The papers—published in Human Psychopharmacology: Clinical & Experimental in 2012 and Psychiatry and Clinical Neurosciences in 2014—examined the safety and effectiveness of an antipsychotic drug in patients with schizophrenia.

According to the retraction notice in Psychiatry and Clinical Neurosciences, the ethics committee at St. Marianna University School of Medicine in Kawasaki found that “the trial included subjects who did not satisfy inclusion criteria.” For instance, not all patients provided written informed consent. But the university found no evidence for data falsification or fabrication.

A spokesperson for Human Psychopharmacology told us: Continue reading Uni dings schizophrenia studies for problems with informed consent, other flaws

Following uproar, surgery journal retracts paper with male-only pronouns

The Annals of Surgery has retracted a paper that used only male pronouns to describe surgeons following outcry from readers.

The journal plans to replace the article — a recent presidential address of the European Surgical Association — with a new version with more “gender inclusive language.”

The problem, said editor Keith D. Lillemoe, is that the address was delivered in April by previous ESA president Marek Krawczyk in Polish. According to an email Krawczyk sent to ESA leadership, which Lillemoe forwarded to us, Krawczyk says the pronoun “his” can include women in Polish.

Still, Lillemoe told us, the journal believed it needed to quickly retract the paper:

Continue reading Following uproar, surgery journal retracts paper with male-only pronouns

Work by group at Australian university faces scrutiny

A journal is investigating research by a group in Australia, after receiving “serious allegations” regarding a 2017 paper about treating eye burns.

The journal, Frontiers in Pharmacology, has issued an expression of concern (EOC) for the 2017 paper while it investigates. The notice does not specify the nature of the allegations.  Meanwhile, several other papers by the three researchers, based at Deakin University in Geelong, Australia, have also come under scrutiny. Late last month, Frontiers in Pharmacology retracted a 2015 paper by Kislay Roy, Rupinder Kanwar, and Jagat R Kanwar, citing image duplication. A 2015 paper in Biomaterials received a correction in May 2017, again flagging image duplication.

Roy, the first author on the papers, is a postdoctoral research fellow; Rupinder Kanwar, a middle author, is a senior lecturer; and Jagat R Kanwar, the corresponding author on all three, is head of the Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research.

Gearóid Ó Faoleán, the ethics and integrity manager at Frontiers in Pharmacology, explained that the investigation into the flagged article is ongoing and the EOC “must serve as the extent of our public statement for the present.”

A spokesperson for Deakin University declined to comment on the allegations: Continue reading Work by group at Australian university faces scrutiny

Months after neuroscientist flagged errors, Nature journal corrects them — and more

When a neuroscientist noticed there were problems with his January 2017 paper in Nature Neuroscience, he didn’t wait for the journal to take action — instead, he published his concerns about four figures on PubMed Commons. Months later, the journal has issued formal corrections to those figures — along with several more.   

In February 2017, we praised Garret Stuber for alerting the scientific community to issues in his paper only 10 days after it first appeared online. On Twitter, he directed followers to the comment on PubMed Commons and asked them to retweet “for the sake of science integrity” — yet another example of how more researchers are taking matters into their own hands to alert readers to flaws in their papers. But according to the journal, the problems with the paper were more extensive than Stuber initially reported. Continue reading Months after neuroscientist flagged errors, Nature journal corrects them — and more

“We do not want to create false hope”: Authors retract Cell paper they can’t replicate

A few years ago, researchers in Sweden had something to celebrate: They thought they had discovered a chink in the armor of the most common type of malignant brain cancer.

In a 2014 Cell paper, the team — led by Patrik Ernfors at the Karolinska Institutet — reported that they had identified a small molecule that could target and kill glioblastoma cells — the cancer that U.S. Senator John McCain was just diagnosed with — and prolong survival in mice with the disease. 

Satish Srinivas Kitambi, the paper’s first author, who is also based at the Karolinska Institutet, said the results got the team “really excited:” Continue reading “We do not want to create false hope”: Authors retract Cell paper they can’t replicate